The standard defense of pharmaceutical pricing goes like this: drug development is expensive and risky, patents allow companies to recoup their investment, and without the profit incentive, new drugs would not get made. This argument contains enough truth to be useful as cover. It omits enough reality to be actively misleading.

Here is what actually drives pharmaceutical pricing: the systematic exploitation of the patent system to maintain monopoly pricing long after the original innovation — if there was meaningful innovation at all — has been fully recouped. The industry calls this portfolio management. A more accurate term is rent extraction.

The Evergreening Playbook

A pharmaceutical patent lasts 20 years from filing. By the time a drug completes clinical trials and receives FDA approval, the effective patent protection period is typically 10 to 12 years. When that protection expires, generic manufacturers can enter the market and prices typically fall by 80 to 90 percent.

The industry's response to patent expiration is not to develop new drugs. It is to extend the monopoly on existing ones.

Evergreening is the practice of obtaining new patents on minor modifications to existing drugs: a new dosage form, a new delivery mechanism, a new salt formulation, a new coating, a new combination with another drug. None of these modifications meaningfully improve the therapeutic effect of the drug. All of them qualify for new patent protection. All of them allow the company to market a "new" version and steer patients and prescribers toward it before the original formulation loses patent protection.

AbbVie's Humira — the best-selling drug in American pharmaceutical history, generating over $200 billion in revenue — was protected by over 130 patents. The core biologic compound was developed using NIH funding. The drug received FDA approval in 2002. AbbVie filed patents continuously for two decades covering the drug's formulation, its dosing, its delivery device, its concentration, its manufacturing process. Biosimilar competitors were blocked from the US market until 2023, two decades after the original approval.

The price of Humira in the United States was approximately $2,900 per month by 2022. The price of Humira biosimilars in Europe, where the patent thicket was less effective, was approximately $600 per month. The difference is not explained by manufacturing costs or research investment. It is explained by the patent strategy.

The NIH Funding Problem

A 2018 study in the Proceedings of the National Academy of Sciences examined every drug approved by the FDA between 2010 and 2016 and found that all 210 drugs traced their origins to NIH-funded research. Every single one. The total NIH contribution to those drugs was approximately $100 billion in public funding.

The drugs developed on the basis of that public research are then sold at prices that put them out of reach for many of the taxpayers who funded the research. The companies that commercialized the research — often purchasing it from universities or small biotech firms that did the early-stage work — are under no legal obligation to price the drugs at any particular level, to license the patents to generic manufacturers, or to account for the public subsidy in their pricing.

This is a transfer of publicly funded research into private monopoly pricing power. It is legal. It is standard practice. And it is the primary mechanism by which the pharmaceutical industry generates its returns.

The Pay-for-Delay System

When a generic manufacturer challenges a pharmaceutical patent, the brand-name company can sue for patent infringement. The litigation process takes time — typically 18 to 30 months. During that period, the generic cannot enter the market.

The industry developed a solution to patent challenges that is considerably cheaper than winning in court: pay the challenger to drop the case. Reverse payment settlements — also called "pay-for-delay" agreements — involve the brand-name company paying the generic manufacturer a sum of money in exchange for the generic agreeing not to enter the market until an agreed future date, typically years away.

The Federal Trade Commission estimated that pay-for-delay agreements cost consumers approximately $3.5 billion per year in higher drug prices. The Supreme Court ruled in 2013 that such settlements could violate antitrust law and must be evaluated under a "rule of reason" standard. The FTC has continued to bring cases. The practice continues.

The R&D Myth

The pharmaceutical industry spent approximately $83 billion on research and development in 2019. It spent approximately $30 billion on direct-to-consumer advertising in the same year — a category of spending that is legal in only two countries in the world (the United States and New Zealand). It spent an additional $20 billion or more on marketing to physicians.

The claim that high drug prices are necessary to fund research becomes harder to sustain when the industry spends more on marketing than on basic research, when it acquires most of its most promising pipeline drugs by purchasing small biotechs that conducted the actual research, and when a significant portion of its formal R&D spending goes toward the evergreening modifications described above rather than genuinely novel compounds.

The 10 largest pharmaceutical companies collectively spent approximately $77 billion on stock buybacks between 2016 and 2020. Stock buybacks transfer money from the company's balance sheet directly to shareholders by repurchasing shares and increasing earnings per share. They do not fund drug discovery. They do not lower drug prices. They enrich existing shareholders at the expense of investment in future products.

The Insulin Case Study

Insulin was discovered in 1921 by Frederick Banting and Charles Best at the University of Toronto. Banting sold the patent for $1 specifically because he believed a life-saving medication should be universally accessible. The patent was donated to the University of Toronto and licensed at minimal cost.

A century later, three companies — Eli Lilly, Novo Nordisk, and Sanofi — control approximately 90% of the global insulin market. They hold hundreds of patents on insulin formulations and delivery devices. The price of insulin in the United States is approximately 10 times the price in comparable wealthy nations. Approximately 1 in 4 American diabetics rationed their insulin in 2019 due to cost. Some died as a result.

The insulin molecules themselves are no longer under patent. The patents are on the formulations, the delivery devices, the manufacturing processes, and the concentrations. The market power derives not from invention but from the sustained, systematic construction of patent barriers around a century-old discovery that was intended to be freely available.

This is the pharmaceutical industry's core business model in concentrated form: take existing knowledge, wrap it in intellectual property, and extract rent from people who need it to live.